Predictive Oncology Announces CEO Retirement
“It has been a privilege to create and lead a team that embraces innovative ideas that will impact the future of oncology drug development," said
“We appreciate the vision that Mel has brought to the company and the impact he has made on our strategic positioning, which sets us up for the next stage of growth,” said
Among his achievements at POAI, Engle led the effort to acquire zPREDICTA, with the goal to broaden the company’s offerings with the production of 3D tumor models in oncology drug development.
Public Relations Contact:
Investor Relations Contact:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
Source: Predictive Oncology Inc.